索拉非尼对中晚期肝细胞癌患者的影响.pdfVIP

·1378 · 沈 茜，等 索拉非尼对中晚期肝细胞癌患者的影响 索拉非尼对中晚期肝细胞癌患者的影响 1 2 2 1 1 沈 茜 ，周益龙 ，邵冰峰 ，田思源 ，徐爱兵 Ｔｈｅ ｅｆｆｅｃｔ ｏｆ ｓｏｒａｆｅｎｉｂ ｉｎ ａｄｖａｎｃｅｄ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ ｐａｔｉｅｎｔｓ 1 2 2 1 1 hen Qian ，Zhou Yilong ，hao Bingfeng ，Tian iyuan ，Xu Aibing 1 2 Department of Medical Oncology；Department of Hepatobiliary Surgery，Nantong ancer Hospital，JiangsuNantong 226361，hina. 【Abstract】 Objective：To observe theincidenceof sorafenib-relatedadversedrugreactionsofpatientswithtermi- nal-stage hepatocellular carcinoma after the treatment，and evaluate the effect and the influence on quality of life of patients six monthsafter sorafenibtreatment.Methods：orafenib-relatedadversedrugreactionsin36 hepatocellular carcinoma cases after treatment were graded，recorded and statistically analyzed.The effect of sorafenib treatment was evaluated according to RECI T criteria six months later.The quality of life of the patients were compared before and six months after treatment using EORTC QLQ-C30.Results：The adverse drug reactionswere hand-foot skin reac- tion，diarrhea，rashes，high blood pressure and so on after sorafenib treatment.The overall response rate was75％ six months after treatment.The scores of physical，role，cognitive，emotion and social functioning were increased and the scores of symptom scaleswere decreased except diarrhea in patients after sorafenib treatment，which had statistical difference P ＜0.05 ）.The global quality of life were much significantly improved than before thetreatment P＜ 0.05）.Conclusion：orafenib as a molecular targeted therapy drug，canprolong survival inpatientswith hepatocellu- larcarcinomaandthetolerabilitytoadversedrugreactionsarebetter，whilethequalityoflifeonpatientscanimprove. 【Key